Pictet Biotech P Dist GBP
At a glance
| Initial charge | 5.00% |
|---|---|
| Initial saving | 4.25% |
| Annual charge | 1.60% |
| Annual saving | 0.000% ² |
| Total Expense Ratio | 1.96% |
| Launch date | 01-12-1995 |
| Launch price | $67.19 |
| Sector | Offshore |
| Fund size | $2,196 million |
| Number of holdings | 39 |
| Fund type | OEIC |
| Type of units | Income |
Ways to Invest
Find out how to invest in this fundHL Research - Our view on this Fund
Full research
About the Fund Manager
Michael Sjöström
Located in: Montreal, Canada
Michael Sjöström, CFA, is the founder and Chief Investment Officer of Sectoral Asset Management which he founded in October 2000. He is the senior Fund Manager for the Pictet Biotech fund since its inception. Prior to founding Sectoral Asset Management, Michael worked for 8 years at Pictet & Cie as Deputy Head of the Swiss Research Team and as a financial analyst covering the pharmaceutical and biotechnology sectors in Switzerland and Europe. Michael was also Head of the Global Pharmaceutical Research team. Prior to joining Pictet, Michael spent 3 years at Bordier & Cie covering Swiss equities and managing Swiss equity portfolios. Michael obtained a BA degree from the St. Gallen School of Economics, Business and Public Administration and Law (HSG) with a specialisation in Financial Management and Controlling. Michael is also a Chartered Financial Analyst (CFA) and a founding member of the Swiss Society of Investment Professionals, part of the Association for Investment Management and Research.
Income details
| Running yield | N/a |
|---|---|
| Income paid | N/a |
| Type of payment | No income |
All yields are variable and not guaranteed. There is currently no yield information available for this fund.
Distribution dates
Distribution dates are currently unavailable.
Top 10 holdings
| Novo Nordisk A/S B | 8.16% |
|---|---|
| Amgen | 8.00% |
| Celgene Corp. | 7.74% |
| Genzyme Corp. | 7.32% |
| Myriad Genetics | 5.85% |
| Vertex Pharmaceuticals | 4.58% |
| Alexion Pharmaceuticals | 4.45% |
| Biogen Idec | 4.27% |
| Illumina | 4.07% |
| Onyx Pharmaceuticals | 3.96% |
Top 10 sectors
| Pharmaceuticals & Biotechnology | 97.69% |
|---|---|
| Cash and Equiv. | 2.18% |
| Non-Classified | 0.14% |
Top 10 countries
| United States | 84.77% |
|---|---|
| Denmark | 9.29% |
| Switzerland | 2.80% |
| Cash and Equiv. | 2.18% |
| Canada | 0.83% |
| Non-Classified | 0.14% |
² Annual saving is not available in the SIPP.
³ If you elect to receive the income from a Vantage ISA, Fund or Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.
Last valuation as at 01-12-2008. Data accurate as at 31/10/2008.
